Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.

计划入组 20 人 · 首次发布于 2006 年 2 月 6 日

Trial to Evaluate the Ability of a Single Infusion of High-Density Lipoprotein (HDL) to Modulate Markers of Cerebral Ischaemia

计划入组 40 人 · 首次发布于 2009 年 1 月 14 日

Mediating Role of Myokines in the Dialogue Between Muscle and Bone Tissue in a Population of Healthy Women Aged 20-89 Years

计划入组 280 人 · 首次发布于 2024 年 11 月 12 日

B cell High Density Microparticles (BioTransplant)

high-density lipoprotein delipidation therapy (Lipid Sciences)

Postsynaptic Density Protein-95 Inhibitors (Johns Hopkins University)

ESSITY AUSTRALASIA PTY LTD

Australia

Essity Hygiene and Health AB

Sweden

ESSITY HMS NORTH AMERICA INC

United States

MediWound Advances EscharEx Phase III Trial and Expands Manufacturing Capacity Ahead of Key 2026 Milestones

Lixte Biotechnology Faces Nasdaq Delisting Over Equity Shortfall, Plans Compliance Measures

Clinical Trial Diversity Lacking Despite FDA Guidelines: Multiple Myeloma Study Highlights Disparities